Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 5 |
| 1.1 List of Tables | 7 | 1 |
| 1.2 List of Figures | 7 | 2 |
| 2 Contract Research Outsourcing Introduction | 9 | 2 |
| 2.1 GBI Research Report Guidance | 10 | 1 |
| 3 Contract Research Outsourcing Overview | 11 | 8 |
| 3.1 Global Contract Research Outsourcing | 11 | 1 |
| 3.1.1 The Clinical Research Process | 12 | 1 |
| 3.1.1.1 Drug Discovery Phase | 12 | 1 |
| 3.1.1.2 Pre-Clinical Phase | 13 | 1 |
| 3.1.1.3 Phase I | 13 | 1 |
| 3.1.1.4 Phase III | 13 | 1 |
| 3.1.1.5 Review and Approval from the Regulatory Agencies | 13 | 1 |
| 3.1.1.6 Post-Marketing Studies | 13 | 1 |
| 3.2 Outsourcing of Clinical Research and Trial Processes | 13 | 1 |
| 3.2.1 Clinical Research Outsourcing is Seen as a Solution to Problems Such as Rising Costs or Low Productivity | 14 | 1 |
| 3.2.2 Strategic Outsourcing Delivers Greater Value by Understanding the Core Competencies of the Vendor and Outsourcing Companies | 14 | 1 |
| 3.3 Key Reasons for Outsourcing to Contract Research Organizations | 14 | 1 |
| 3.3.1 Desire to Reduce Costs is a Prime Reason for Contract Research Outsourcing | 15 | 1 |
| 3.3.2 Contract Research Organizations are Engaged in Reducing Time to Market in Order to Achieve a Competitive Edge | 15 | 1 |
| 3.3.3 Outsourcing Critical but Resource and Time Intensive Functions such as Data Management Allows Biopharmaceutical Companies to Focus on Core Competencies | 16 | 1 |
| 3.3.4 Evolving Risk Sharing Agreements Attract Biopharmaceutical Companies to Increase Contract Research Outsourcing | 16 | 1 |
| 3.3.5 Contract Research Organizations are Helping to Improve Clinical Research Quality Through Better Regulatory Understanding and Keeping Pace with Technological Advances | 17 | 1 |
| 3.3.6 Small and Medium Biopharmaceutical Companies can Leverage on the Resources of Contract Research Organizations | 17 | 1 |
| 3.3.7 Biopharmaceutical Companies Benefit from New Technologies that Contract Research Organization Have Access to | 17 | 2 |
| 4 Contract Research Outsourcing Service Models | 19 | 8 |
| 4.1 Contract Research Outsourcing Service Model | 19 | 1 |
| 4.1.1 Fully Integrated Service Model | 19 | 1 |
| Functional Service Model | 20 | 1 |
| 4.2 Criteria for Selecting a Contract Research Organization | 21 | 1 |
| Early Stage Drug Development Outsourcing | 22 | 1 |
| 4.3.1 Strategic or Tactical Advantages of Outsourcing | 22 | 1 |
| 4.3.2 Case Study | 22 | 1 |
| 4.3.2.1 Long Term Partnerships with Drug Discovery Service Provider | 22 | 1 |
| 4.4 Clinical Stage Drug Development Outsourcing | 23 | 1 |
| 4.4.1 Strategic or Tactical Advantages of Outsourcing | 23 | 1 |
| 4.4.2 Case Studies | 23 | 1 |
| 4.4.2.1 A Strategic Move by a Large Pharmaceutical Company | 23 | 1 |
| 4.4.2.2 End-to-End Clinical Data Management Solutions | 24 | 1 |
| Late Stage Development Outsourcing | 25 | 1 |
| 4.5.1 Strategic or Tactical Advantages of Outsourcing | 25 | 1 |
| 4.5.1.1 Innovative Techniques by a Contract Research Organization to Finish the Targets in Specific Timeframes | 25 | 2 |
| 5 Contract Research Outsourcing Market Characterization | 27 | 12 |
| The Contract Research Outsourcing Market will Continue to Grow, Driven by the Demand by the Biopharmaceutical Industry | 27 | 1 |
| 5.2 Key Market Drivers | 28 | 1 |
| 5.2.1 Increasing R&D Expenditure and Decreasing Productivity in the Biopharmaceutical Industry - Promoting R&D Outsourcing | 28 | 3 |
| 5.2.2 Stringent Regulations and Complex Clinical Trials Forcing Biopharmaceutical Companies to Leverage on the Contract Research Organizations | 31 | 1 |
| 5.2.3 Restriction on Pricing and Reimbursement of Drugs Need for Managing Costs from Earliest Stages of Development | 31 | 1 |
| 5.2.4 The Increasing Number of Clinical Trials | 32 | 1 |
| 5.3 Key Market Restraints/ Challenges | 33 | 1 |
| 5.3.1 Quality Concerns | 33 | 1 |
| 5.3.2 Economic Recession | 34 | 1 |
| 5.4 Contract Research Outsourcing Market Trends | 34 | 1 |
| 5.4.1 The Number of Services Focusing on the Late Stage Clinical Development is Increasing | 35 | 1 |
| 5.4.2 The Clinical Research and Trials are Becoming more Globalized | 36 | 1 |
| 5.4.3 Pharmaceutical Companies are Moving to Strategic Partnerships with Contract Research Organizations | 37 | 1 |
| 5.4.4 Emerging Tools to Enhance Drug Discovery Process Will be Key Drivers in the Future | 37 | 1 |
| Contract Research Outsourcing Unmet Needs | 38 | 1 |
| 5.5.1 High Technology Needs and Integration | 38 | 1 |
| 5.5.2 Lack of Therapeutic Expertise | 38 | 1 |
| 5.5.3 Contract Research Organizations are Short of Experienced Research Professionals to Conduct the Clinical Trial Studies | 38 | 1 |
| 6 Contract Research Outsourcing Geographical Landscape | 39 | 5 |
| 6.1 Emerging Regions in the Global Contract Research Outsourcing Market | 40 | 1 |
| 6.1.1 Latin America | 40 | 1 |
| 6.1.1.1 Potential Advantages of the Latin American Contract Research Outsourcing Market | 40 | 1 |
| 6.1.2 Central and Eastern Europe (CEE) | 40 | 1 |
| 6.1.2.1 Potential Advantages of Central and East European Contract Research Outsourcing Market | 41 | 1 |
| 6.1.3 India | 41 | 1 |
| 6.1.3.1 Potential Advantages of the Indian Contract Research Outsourcing Market | 42 | 1 |
| 6.1.4 China | 42 | 1 |
| 6.1.4.1 Potential Advantages of the Chinese Contract Research Outsourcing Market | 43 | 1 |
| 7 Contract Research Outsourcing Regulatory Issues | 44 | 4 |
| 7.1 Contract Research Organizations are Subject to the Same Regulations as Biopharmaceutical Companies | 44 | 1 |
| 7.1.1 Regulation in the Drug Discovery Stage | 45 | 1 |
| 7.1.2 Regulation in the Preclinical Stage | 45 | 1 |
| 7.1.2.1 The Principles of Good Laboratory Practice | 45 | 1 |
| 7.1.3 Regulation in the Clinical Trials Stage | 45 | 1 |
| 7.1.3.1 The Principles of Good Clinical Practice | 46 | 1 |
| 7.2 Regulations Governing Outsourcing to Other Regions | 46 | 1 |
| 7.2.1.1 FDA Requirements for Outsourcing | 47 | 1 |
| 7.2.1.2 European Union Requirements for Outsourcing | 47 | 1 |
| 7.2.1.3 Requirements in Emerging Countries | 47 | 1 |
| 8 Contract Research Outsourcing Competitive Landscape | 48 | 11 |
| 8.1 Overview | 48 | 1 |
| 8.2 Market Share Analysis | 49 | 1 |
| 8.3 Competitive Profiling | 50 | 1 |
| 8.4 Quintiles Transnational Corp. | 51 | 1 |
| 8.4.1 Snapshot | 51 | 1 |
| 8.4.2 Business Description | 51 | 1 |
| 8.4.3 Recent M&A Deals and Strategic Alliances | 51 | 1 |
| 8.4.3.1 Strategic Alliance Agreement with the University of Pretoria | 51 | 1 |
| 8.4.3.2 Quintiles to Open Phase I Unit in India | 52 | 1 |
| 8.4.3.3 Quintiles Acquires Targeted Molecular Diagnostics | 52 | 1 |
| 8.4.3.4 QPS and Quintiles Collaborates for Cardiac Safety Service | 52 | 1 |
| 8.4.3.6 Quintiles to Provide Central Lab Services in Japan | 52 | 1 |
| 8.5 Covance Inc. | 53 | 1 |
| 8.5.1 Business Description | 53 | 1 |
| 8.5.2 Recent M&A Deals and Alliances | 53 | 1 |
| 8.5.2.1 Covance Agreed to Provide Genomic Analysis Services to Merck &Co., Inc. | 53 | 1 |
| 8.5.2.2 Covance Enters into a Multi-Year Marketing Agreement with Phase Forward | 53 | 1 |
| 8.5.2.3 Covance Acquired Swiss-Based Early Clinical Development Site | 54 | 1 |
| 8.5.2.4 Covance Purchased Equity Stake in Caprion Proteomics | 54 | 1 |
| 8.5.2.5 Covance and Eli Lilly Entered into a Strategic R&D Collaboration | 54 | 1 |
| 8.5.2.6 Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China | 54 | 1 |
| 8.6 Pharmaceutical Product Development (PPD) Inc. | 54 | 1 |
| Business Description | 54 | 1 |
| 8.6.2 Recent M&A Deals and Alliances | 55 | 1 |
| 8.6.2.1 PPD Acquired AbCRO | 55 | 1 |
| 8.6.2.2 PPD Acquired Magen BioSciences | 55 | 1 |
| 8.6.2.3 PPD Expands Post-Approval Drug Safety Capabilities through Strategic Alliance with WHISCON | 55 | 1 |
| 8.6.2.4 PPD Enters Into Strategic Collaboration with Merck | 55 | 1 |
| 8.6.2.5 PPD Acquired InnoPharm | 55 | 1 |
| 8.7 Charles River Laboratories International, Inc. | 56 | 1 |
| 8.7.1 Business Description | 56 | 1 |
| 8.7.2 Recent M&A Deals and Alliances | 57 | 1 |
| 8.7.2.1 Charles River Acquired Cerebricon LTD | 57 | 1 |
| 8.7.2.2 Charles River Acquired Systems Pathology Company | 57 | 1 |
| 8.7.2.4 Charles River Acquired Molecular Imaging Research (MIR ) Preclinical Services | 57 | 1 |
| 8.8 PAREXEL International | 57 | 1 |
| 8.8.1 Business Description | 58 | 1 |
| 8.8.2 Recent M&A Deals and Alliances | 58 | 1 |
| 8.8.2.1 Perceptive Informatics Enhances Musculoskeletal Medical Imaging Capabilities through Alliance with Optasia | 58 | 1 |
| 8.8.2.2 Perceptive Informatics Enhances CNS and Oncology Medical Image Processing and Analysis Capabilities through Alliance with Biospective | 58 | 1 |
| 8.8.2.3 PAREXEL Establishes Alliance with SITS | 58 | 1 |
| 9 Contract Research Outsourcing Deals Analysis | 59 | 6 |
| 9.1 Mergers and Acquisitions | 59 | 1 |
| 9.1.1 Quintiles Acquires Targeted Molecular Diagnostics | 60 | 1 |
| 9.1.2 Quintiles Acquires Bio-Trials | 60 | 1 |
| 9.1.3 PPD Acquired Magen BioSciences | 60 | 1 |
| 9.1.5 ICON Acquires Prevalere Life Sciences Inc. | 60 | 1 |
| 9.1.6 ICON Acquires DOCS International | 61 | 1 |
| 9.1.7 MDS Inc Acquires Molecular Devices Corporation | 61 | 1 |
| 9.1.8 Kendle Acquires International Clinical Research | 61 | 1 |
| 9.1.9 PRA International Acquires Pharma Bio-Research | 61 | 1 |
| 9.2 Strategic Alliances, Service Agreements and Other Deals | 61 | 1 |
| 9.3 Deals by Year | 62 | 1 |
| Deals by Therapeutic Area | 63 | 2 |
| 10 Contract Research Outsourcing Appendix | 65 | 5 |
| 10.1 Market Definitions | 65 | 1 |
| 10.2 Abbreviations | 65 | 1 |
| 10.3 Sources | 66 | 1 |
| 10.4 Methodology | 66 | 3 |
| 10.4.1 Coverage | 67 | 1 |
| 10.4.2 Secondary Research | 67 | 1 |
| 10.4.3 Primary Research | 68 | 1 |
| 10.4.4 Expert Panel Validation | 68 | 1 |
| 10.5 Contact Us | 68 | 1 |
| 10.6 Disclaimer | 68 | 2 |